Company Overview
Creative Medical Technology Holdings, Inc. operates as a commercial-stage biotechnology entity dedicated to developing novel biological therapeutics across specialized medical fields including immunotherapy, endocrinology, urology, neurology, and orthopedics within the United States. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry where innovation in drug development and clinical applications drives value creation. Currently, the organization employs four individuals and maintains a total market capitalization of $7.28M alongside an annual revenue base of $6,000 over the trailing twelve months. These specific financial figures indicate that the company is an extremely small-cap entity with minimal revenue generation relative to its market valuation, suggesting it is likely in a pre-revenue or early-stage commercialization phase where cash reserves are critical for sustaining operations rather than generating profit.
Financial Health
The company reported a revenue of $6,000 for the trailing twelve months, yet recorded a net income of $-5,995,008 and an EBITDA of $-6,019,487. The substantial gap between the nominal revenue of $6,000 and the massive net loss of approximately $6.0 million reveals a cost structure dominated by research, development, and administrative expenses that far exceed any current sales income. Free cash flow stands at $-3,751,198, which indicates a significant cash burn rate that the company must fund through external capital markets or existing reserves to maintain its operational runway. Gross margin is reported at 63.4%, while operating margin is listed as -64859.4% and profit margin at 0.0%, illustrating that while the cost of goods sold is relatively low compared to sales, the overwhelming operational expenses have rendered operating profitability impossible to calculate meaningfully at this scale. On the balance sheet, the company holds $7.21M in cash against total debt of $14,194, resulting in a debt-to-equity ratio of 0.19. This disparity between liquid assets and liabilities suggests a highly conservative balance sheet structure where solvency is not currently threatened by leverage. The current ratio is 25.97, a figure that indicates exceptional short-term liquidity, meaning the company possesses more than twenty-five times the current assets necessary to cover its immediate obligations. Furthermore, the return on equity is -86.5% and the return on assets is -53.0%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the lack of profitable earnings to generate returns.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E is -1.46, implying that the market is currently pricing in an expectation of continued losses or a turnaround that has not yet materialized in earnings per share. The price-to-book ratio is 0.97, indicating that the market values the company at approximately 97% of its book value, which suggests the stock is trading at a slight discount to its tangible asset base rather than a premium. The price-to-sales ratio is extremely elevated at 1213.74, and the EV/EBITDA is -0.02, figures that suggest the market is valuing the company primarily on potential future growth or asset potential rather than current cash flow or sales performance. The stock has a 52-week high of $6.25 and a 52-week low of $1.50, meaning the current price sits within a volatile range where it could be trading anywhere between 100% below the high or significantly above the low depending on the exact current share price not explicitly defined in the static data provided. The beta is 2.15, which indicates that the stock price is expected to be approximately twice as volatile as the broader market, exposing investors to significantly higher fluctuations in value during periods of market stress or rally.
Growth & Income
Revenue growth year-over-year is 0.0%, and earnings growth year-over-year is N/A, indicating that the company is currently static in terms of top-line expansion and that there are no comparable earnings figures to measure growth trajectories against. Since the company is not generating positive earnings, it does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow must be directed toward sustaining operations and funding research rather than being distributed to shareholders. The absence of a dividend yield confirms that the company reinvests all available liquidity into its biotechnology development pipeline rather than providing income to investors. The overall growth and income profile is characterized by zero current revenue expansion, negative earnings growth potential, and a total lack of dividend income, reflecting a high-risk, high-volatility investment vehicle typical of early-stage biotechnology firms.